Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
+$0.05 today
- Market cap
- $191.64M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
Volume 0.26M
Average 0.32M
Returns on capital
Galectin Therapeutics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
24.4%
avg -259.6%
ROIC
-174.3%
avg -390.1%
ROA
-157.9%
avg -153.7%
Analysis
ROE is currently the strongest return metric at 24.4% versus its period average of -259.6%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Joel Lewis | President & CEO | USD 992.02K | 56 | 91.00K | 0.14% |
Khurram Jamil | Chief Medical Officer | USD 921.58K | 50 | 0 | <0.01% |
Jack W. Callicutt | Chief Financial Officer, Treasurer & Corporate Secretary | USD 676.02K | 59 | 65.00K | 0.10% |
Jim Wilkins | Head of CMC & Pharmaceutical Development | — | — | — | — |
Robert Tritt | General Counsel | — | — | — | — |
Beth Knowles | Executive Assistant & Officer Manager | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 14, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$22,935.00
Sells
37
$4.82M
Net Transaction Value
−$4.80M
Net selling
Most Active
Shlevin Harold H.
14 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 14, 26Jul 14, 2026 | Jamil Khurram Direct | Sell | $83.3K$83,284.50 |
| Jun 29, 26Jun 29, 2026 | Shlevin Harold H. Direct | Sell | $112.2K$112,230.72 |
| Jun 29, 26Jun 29, 2026 | Jamil Khurram Direct | Sell | $239.2K$239,233.68 |
| Jun 26, 26Jun 26, 2026 | Shlevin Harold H. Direct | Sell | $38.7K$38,660.00 |
| Jun 26, 26Jun 26, 2026 | Jamil Khurram Direct | Sell | $12.7K$12,665.00 |
| Jun 23, 26Jun 23, 2026 | Jamil Khurram Direct | Sell | $23.7K$23,728.98 |
| May 26, 26May 26, 2026 | Jamil Khurram Direct | Sell | $1.8K$1,761.03 |
| Feb 6, 26Feb 6, 2026 | ELDRED KARY Direct | Buy | $810$810.00 |
| Jan 6, 26Jan 6, 2026 | CALLICUTT JACK W Direct | Sell | $74.7K$74,695.11 |
| Jan 6, 26Jan 6, 2026 | Jamil Khurram Direct | Sell | $78.2K$78,204.98 |
1–10 of 40
Summary
Insiders reported 3 buys worth $22,935.00 and 37 sells worth $4.82M over the last 12 months. That adds up to net selling of $4.80M. Shlevin Harold H. was the most active insider with 14 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Galectin Therapeutics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about GALT's management, answered from reported figures.
Who manages GALT?
Galectin Therapeutics Inc. (GALT) lists 6 active executives. The top listed executive is Khurram Jamil, Chief Medical Officer.
Are GALT insiders buying or selling?
Recent insider activity shows net buying of $102.85M.
Continue the stock analysis
Jump to another research area for this company.